UroGen Pharma Ltd. reiterated revenue guidance for the full year 2023. The Company reiterates anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 million to $86 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.19 USD | -4.28% | +1.70% | -12.07% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.07% | 477M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.26% | 22.28B | |
-11.90% | 22.41B | |
-5.71% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023